Amgen Inc. has been developing products in Japan via JVs and partnerships since the early 1980s. Now a new joint venture with Astellas Pharma Inc. will allow the biotech to build its first commercial presence in that country.

Amgen wasted no time adding products to its Japanese portfolio with last week's deal for Japanese rights to a heart failure candidate from Cytokinetics Inc.